
INSP Stock Forecast & Price Target
INSP Analyst Ratings
Bulls say
Inspire Medical Systems is experiencing a period of decelerating growth due to coding and reimbursement challenges, resulting in a decrease in guidance and uncertainty around their near-term growth profile. However, their hypoglossal nerve stimulation device offers a safe and effective treatment for OSA, and with a new product cycle coming in 2027, there is potential for increased adoption and market penetration. They have a strong cash position, high GM profile, and EPS profitability which may provide some support for their stock price, but limited near-term multiple expansion is expected until there is more confidence in estimate upside.
Bears say
Inspire Medical Systems is facing challenges in their revenue growth due to uncertainties surrounding reimbursement coding guidelines and the WISeR program. Despite the recent launch of Inspire V, there are still concerns about competition, capacity constraints, and GLP-1 related issues. With the recent guidance revision and expected negative growth through 2026, it may be difficult for the stock to recover in the near term.
This aggregate rating is based on analysts' research of Inspire Medical Systems Inc and is not a guaranteed prediction by Public.com or investment advice.
INSP Analyst Forecast & Price Prediction
Start investing in INSP
Order type
Buy in
Order amount
Est. shares
0 shares